Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : CDC Advisory Unanimously Recommends Pfizer/BioNTech COVID Booster For Adults 65 Years and Older

09/23/2021 | 04:12pm EDT


ę MT Newswires 2021
All news about PFIZER, INC.
10/26Swissmedic OKs Pfizer/BioNTech COVID-19 Booster Jabs For High Risk People
MT
10/26Pfizer, BioNTech Get US FDA Panel's Endorsement for COVID-19 Vaccine in Children 5 and ..
MT
10/26FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the P..
BU
10/26FDA Panel Recommends Authorization of Pfizer/BioNTech COVID-19 Vaccine for Kids Aged 5 ..
MT
10/26U.S. administers over 415 mln doses of COVID-19 vaccines - CDC
RE
10/26TRILLIUM THERAPEUTICS BRIEF : Securityholders Approve Acquisition by Pfizer
MT
10/26Trillium Securityholders Approve Acquisition by Pfizer
AQ
10/26Health Care Up Amid Drug Development Hopes -- Health Care Roundup
DJ
10/26PRESS RELEASE : FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorizat..
DJ
10/26PRESS RELEASE : FDA Advisory Committee Votes in -2-
DJ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,8x
Yield 2021 3,62%
Capitalization 244 B 244 B -
EV / Sales 2021 3,35x
EV / Sales 2022 3,82x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 43,56 $
Average target price 45,72 $
Spread / Average Target 4,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.17.22%244 227
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
ELI LILLY AND COMPANY47.15%222 158
MERCK & CO., INC.-0.17%206 712